Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Endometrial HyperplasiaEndometrial CancerGynecologic Cancer
Interventions
PROCEDURE

Hysteroscopic uterine resection

"Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications."

Trial Locations (1)

V5Z 1M9

RECRUITING

Vancouver General Hospital, Vancouver

All Listed Sponsors
collaborator

University of British Columbia

OTHER

lead

Vancouver Coastal Health Research Institute

OTHER